Belluna Co., Ltd. (TYO:9997)

Intercept Pharmaceuticals Income Statement

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	210,314	210,856	208,298	212,376	220,128	206,499
Revenue Growth (YoY)	1.20%	1.23%	-1.92%	-3.52%	6.60%	14.75%
Cost of Revenue	80,756	81,604	81,953	86,674	90,822	84,943
Gross Profit	129,558	129,252	126,345	125,702	129,306	121,556
Selling, General & Admin	115,874	116,177	115,385	113,302	114,292	104,277
Other Operating Expenses	235	235	310	380	444	852
Operating Expenses	117,083	117,386	116,579	114,505	115,498	105,842
Operating Income	12,475	11,866	9,766	11,197	13,808	15,714
Interest Expense	-906	-783	-481	-343	-246	-201
Interest & Investment Income	1,184	1,236	1,050	476	574	610
Currency Exchange Gain (Loss)	554	907	1,472	905	540	59
Other Non Operating Income (Expenses)	-475	28	25	223	-141	688
EBT Excluding Unusual Items	12,832	13,254	11,832	12,458	14,535	16,870
Gain (Loss) on Sale of Investments	333	333	1,376	-32	1,398	-67
Gain (Loss) on Sale of Assets	-27	-27	15	11	-391	1,210
Asset Writedown	-202	-205	-3,449	-484	-225	-204
Legal Settlements	-14	-14	-	-	-5	-64
Other Unusual Items	-131	-131	-1	-	-1	-2
Pretax Income	12,791	13,210	9,773	11,953	15,311	17,743
Income Tax Expense	4,213	4,381	4,055	4,497	5,047	6,723
Earnings From Continuing Operations	8,578	8,829	5,718	7,456	10,264	11,020
Minority Interest in Earnings	-36	-32	121	-39	-60	16
Net Income	8,542	8,797	5,839	7,417	10,204	11,036
Net Income to Common	8,542	8,797	5,839	7,417	10,204	11,036
Net Income Growth	56.79%	50.66%	-21.27%	-27.31%	-7.54%	88.26%
Shares Outstanding (Basic)	96	96	97	97	97	97
Shares Outstanding (Diluted)	96	96	97	97	97	97
Shares Change (YoY)	-0.42%	-0.30%	0.01%	0.01%	0.01%	-0.04%
EPS (Basic)	88.71	91.25	60.39	76.71	105.54	114.17
EPS (Diluted)	88.71	91.25	60.39	76.71	105.54	114.17
EPS Growth	57.45%	51.11%	-21.28%	-27.32%	-7.55%	88.34%
Free Cash Flow	-	-5,342	-2,883	-19,938	-8,646	12,945
Free Cash Flow Per Share	-	-55.41	-29.82	-206.21	-89.43	133.91
Dividend Per Share	29.000	29.000	20.500	20.000	19.000	16.500
Dividend Growth	41.46%	41.46%	2.50%	5.26%	15.15%	3.13%
Gross Margin	61.60%	61.30%	60.66%	59.19%	58.74%	58.87%
Operating Margin	5.93%	5.63%	4.69%	5.27%	6.27%	7.61%
Profit Margin	4.06%	4.17%	2.80%	3.49%	4.63%	5.34%
Free Cash Flow Margin	-	-2.53%	-1.38%	-9.39%	-3.93%	6.27%
EBITDA	18,905	18,197	15,700	15,755	18,167	19,721
EBITDA Margin	8.99%	8.63%	7.54%	7.42%	8.25%	9.55%
D&A For EBITDA	6,430	6,331	5,934	4,558	4,359	4,007
EBIT	12,475	11,866	9,766	11,197	13,808	15,714
EBIT Margin	5.93%	5.63%	4.69%	5.27%	6.27%	7.61%
Effective Tax Rate	32.94%	33.16%	41.49%	37.62%	32.96%	37.89%
Advertising Expenses	-	28,613	29,772	33,082	34,268	32,887

Source: S&P Global Market Intelligence. Standard template. Financial Sources.